---
title: "Pharmaron Beijing Issues Unaudited First-Quarter 2026 Report Under Hong Kong Rules"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284364965.md"
description: "Pharmaron Beijing Co., Ltd. has released its unaudited first-quarter report for 2026, prepared under PRC Accounting Standards and aligned with International Financial Reporting Standards. The announcement, compliant with Hong Kong regulations, details the company's financial performance and governance structure, including its board composition. This transparency aims to bolster investor confidence. The latest analyst rating for Pharmaron's stock (HK:3759) is a Buy, with a price target of HK$28.10. Pharmaron operates in the pharmaceutical sector, providing research and development services."
datetime: "2026-04-28T10:15:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284364965.md)
  - [en](https://longbridge.com/en/news/284364965.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284364965.md)
---

# Pharmaron Beijing Issues Unaudited First-Quarter 2026 Report Under Hong Kong Rules

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an announcement.

Pharmaron Beijing Co., Ltd. has released its unaudited first quarterly report for 2026, prepared primarily under PRC Accounting Standards, with certain sections aligned to International Financial Reporting Standards. The disclosure, made in accordance with Hong Kong listing and securities regulations, informs investors of the company’s early-year financial performance and governance structure, underscoring ongoing regulatory compliance and transparency obligations for stakeholders.

The announcement also reiterates the composition of Pharmaron’s board, including executive, non-executive, employee representative, and independent non-executive directors. This governance detail, together with the timely reporting, highlights the company’s adherence to corporate oversight standards expected of Hong Kong-listed issuers, which may help support investor confidence and enhance its standing in capital markets.

The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.

**More about Pharmaron Beijing Co., Ltd. Class H**

Pharmaron Beijing Co., Ltd. is a China-based joint stock company listed in Hong Kong, operating in the pharmaceutical and life sciences sector. Through its group of subsidiaries, it provides research, development, and related services to drug developers and other industry stakeholders, with its main operations located in Beijing’s Economic Technological Development Area.

**Average Trading Volume:** 5,571,416

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$55.97B

For a thorough assessment of 3759 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [03759.HK](https://longbridge.com/en/quote/03759.HK.md)
- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)

## Related News & Research

- [Pharmaron Beijing Sets Out Board and Committee Structure for Third Board Session](https://longbridge.com/en/news/270177231.md)
- [Livzon Secures Controlling Stake in Vietnam’s Imexpharm After Tender Offer Completion](https://longbridge.com/en/news/285949804.md)
- [Tigermed Says Probe Into Major Shareholders Will Not Hit Operations](https://longbridge.com/en/news/286261011.md)
- [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md)
- [13:45 ETAn InventHelp 123Invent Client Develops New Medication Tracking System (FDD-151)](https://longbridge.com/en/news/285979002.md)